semaglutide biosimilars
Semaglutide Mania in China: Inside the Biosimilar Gold Rush
China’s semaglutide market is heading toward $61B by 2032, unleashing a biosimilar frenzy. Over 25 drugmakers have filed 90+ applications, eight are nearing approval, and a pending patent ruling could trigger price wars that reshape diabetes and obesity care.